Samsung Biologics has acquired PolyPeptide Group AG for an undisclosed amount. This strategic move sees the South Korean biologics contract development and manufacturing organization (CDMO) expand its capabilities into the rapidly growing peptide therapeutics market. PolyPeptide Group, a specialized CDMO for peptide-based active pharmaceutical ingredients (APIs), supports pharmaceutical and biotech customers globally, offering products and services from pre-clinical to commercial stages. The Swiss-listed company, with a history dating back to 1952, operates a global network of six GMP-certified facilities across Europe, the U.S., and India, and holds significant exposure to metabolic diseases, including GLP-1.
The acquisition represents a significant diversification for Samsung Biologics, a prominent player in large-scale biologics manufacturing. By buying PolyPeptide, Samsung Biologics aims to broaden its CDMO service portfolio, addressing the increasing demand for peptide APIs. This expansion allows Samsung Biologics to offer a more comprehensive suite of manufacturing solutions to its global client base, spanning both biologics and peptides.
Strategically, the move positions Samsung Biologics to capitalize on the robust growth within the peptide drug market, particularly in areas like metabolic diseases where PolyPeptide has established a strong presence. The synergy between Samsung Biologics' operational scale and PolyPeptide's specialized peptide development and manufacturing capabilities is expected to create a more integrated and efficient offering for pharmaceutical companies seeking comprehensive CDMO services.
The combined entity is poised to enhance its competitive standing in the global CDMO landscape. This corporate acquisition is anticipated to strengthen the supply chain for critical pharmaceutical ingredients, providing clients with a single partner for a wider range of complex drug modalities and ultimately contributing to the health of millions of patients worldwide.